Overview

A Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline Biologicals' Influenza Vaccine GSK3206641A Administered in Adults 18 to 64 Years of Age and 65 Years of Age and Older

Status:
Active, not recruiting

Trial end date:
2022-10-04

Target enrollment:

Participant gender:

Summary

Study to evaluate the safety and immunogenicity of H7N9 antigen in combination with full or half doses of AS03 adjuvant system in healthy adults.

Phase:

Phase 2

Details

Lead Sponsor:

GlaxoSmithKline